RxDoctor Payments Data

George Hoyek, MD

Geriatric Medicine · Noblesville, INNPI 1255521092

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Tempus AI, Inc at 40.6% of the total.

$309in general payments, 2019–2025

Across 10 payments — averaging $30.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tempus AI, Inc$126
  • Lilly USA, LLC$56
  • UCB, Inc.$54
  • Sunovion Pharmaceuticals Inc.$46
  • Avanir Pharmaceuticals, Inc.$15
  • Johnson & Johnson$14

What the payments were for

  • Food & beverage$309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$309 in reported general payments places this provider in the 55th percentile of 70 geriatric medicine providers in Indiana.

See all geriatric medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$103,866
Medicare patients
493
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban785$240,179
RebifInterferon Beta-1a/Albumin25$151,242
XareltoRivaroxaban169$53,166
EntrestoSacubitril/Valsartan120$51,429
MyrbetriqMirabegron127$32,639
TradjentaLinagliptin96$25,736
Memantine Hcl414$22,267
CreonLipase/Protease/Amylase20$18,955
JardianceEmpagliflozin44$18,549
Atorvastatin Calcium952$16,122
Galantamine Hbr122$10,859
Levothyroxine Sodium761$10,212
GemtesaVibegron23$9,779
Breo ElliptaFluticasone/Vilanterol22$9,634
NamzaricMemantine Hcl/Donepezil Hcl29$9,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$53,166169 claims
Lilly USA, LLCTrulicity$56$5,81013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 70 geriatric medicine providers in Indiana.

Other geriatric medicine in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →